相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effi cacy of a Small-Molecule Inhibitor of Kras G12D in Immunocompetent Models of Pancreatic Cancer
Samantha B. Kemp et al.
CANCER DISCOVERY (2023)
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Matthias Drosten et al.
MOLECULAR ONCOLOGY (2022)
ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability
Nancy H. C. Loos et al.
PHARMACOLOGICAL RESEARCH (2022)
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Desage et al.
FRONTIERS IN ONCOLOGY (2022)
KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors
Guillem Paniagua et al.
MOLECULAR ONCOLOGY (2022)
KRAS is vulnerable to reversible switch-II pocket engagement in cells
James D. Vasta et al.
NATURE CHEMICAL BIOLOGY (2022)
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss et al.
CANCER DISCOVERY (2022)
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Damien Reita et al.
CANCERS (2022)
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
Dylan A. Farnsworth et al.
NPJ PRECISION ONCOLOGY (2022)
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Jill Hallin et al.
NATURE MEDICINE (2022)
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Yihsuan S. Tsai et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition
Hitendra S. Solanki et al.
CLINICAL CANCER RESEARCH (2021)
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao et al.
NATURE (2021)
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Yuta Adachi et al.
CANCERS (2021)
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Takamasa Koga et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka et al.
CANCER DISCOVERY (2021)
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Neal S. Akhave et al.
CANCER DISCOVERY (2021)
The promise and peril of KRAS G12C inhibitors
Amanda R. Moore et al.
CANCER CELL (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Miriam Molina-Arcas et al.
GENES (2021)
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance
Matthew J. Sale et al.
NATURE COMMUNICATIONS (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
Manuel Sanclemente et al.
CANCER CELL (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Yaohua Xue et al.
NATURE MEDICINE (2017)
Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
Wei-Jen Chung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo
Xiaolu Cui et al.
SCIENTIFIC REPORTS (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
David G. McFadden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
Collin M. Blakely et al.
CELL REPORTS (2015)
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Peter M. K. Westcott et al.
NATURE (2015)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia
Eugene Park et al.
BLOOD (2011)
The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro
Philipp Lechler et al.
BMC CANCER (2011)
c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
Rafael B. Blasco et al.
CANCER CELL (2011)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Trever G. Bivona et al.
NATURE (2011)
Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
Annette S. Little et al.
SCIENCE SIGNALING (2011)
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Sergei I. Grivennikov et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains
Lori D. Dwyer-Nield et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D. Ercan et al.
ONCOGENE (2010)
Deletion of the developmentallv essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss
Yaroslava Ruzankina et al.
CELL STEM CELL (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells
T Gritsko et al.
CLINICAL CANCER RESEARCH (2006)
The differential effects of mutant p53 alleles on advanced murine lung cancer
EL Jackson et al.
CANCER RESEARCH (2005)
分享论文
